| Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report P Horby, WS Lim, J Emberson, M Mafham, J Bell, L Linsell, N Staplin, ... MedRxiv, 2020.06. 22.20137273, 2020 | 9096 | 2020 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5293 | 2021 |
| Dexamethasone in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 384 (8), 693-704, 2021 | 2761 | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1747* | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 1447 | 2020 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 443* | 2021 |
| Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease CC Khor, S Davila, WB Breunis, YC Lee, C Shimizu, VJ Wright, ... Nature genetics 43 (12), 1241-1246, 2011 | 375 | 2011 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease D Burgner, S Davila, WB Breunis, SB Ng, Y Li, C Bonnard, L Ling, ... PLoS genetics 5 (1), e1000319, 2009 | 286 | 2009 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 238 | 2022 |
| Adeno-associated virus 2 infection in children with non-A–E hepatitis A Ho, R Orton, R Tayler, P Asamaphan, V Herder, C Davis, L Tong, ... Nature 617 (7961), 555-563, 2023 | 102 | 2023 |
| Experimental treatment of Ebola virus disease with brincidofovir J Dunning, SB Kennedy, A Antierens, J Whitehead, I Ciglenecki, ... PloS one 11 (9), e0162199, 2016 | 101 | 2016 |
| An emergency medicine research priority setting partnership to establish the top 10 research priorities in emergency medicine J Smith, L Keating, L Flowerdew, R O'Brien, S McIntyre, R Morley, ... Emergency Medicine Journal 34 (7), 454-456, 2017 | 80 | 2017 |
| Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease CC Khor, S Davila, C Shimizu, S Sheng, T Matsubara, Y Suzuki, ... Journal of medical genetics 48 (7), 467-472, 2011 | 72 | 2011 |
| Genomic investigations of unexplained acute hepatitis in children S Morfopoulou, S Buddle, OE Torres Montaguth, L Atkinson, ... Nature 617 (7961), 564-573, 2023 | 66 | 2023 |
| International Kawasaki Disease Genetics Consortium: A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease D Burgner, S Davila, WB Breunis, SB Ng, Y Li, C Bonnard, L Ling, ... PLoS Genet 5 (1), e1000319, 2009 | 28 | 2009 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 15 | 2023 |
| A second update on mapping the human genetic architecture of COVID-19 M Kanai, SJ Andrews, M Cordioli, C Stevens, BM Neale, M Daly, A Ganna, ... Nature 621 (7977), E7-E26, 2023 | 14 | 2023 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 8 | 2023 |
| Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose … J Dear Trials 20, 1-11, 2019 | 8 | 2019 |
